Establish a COVID-19 biorepository to aid in developing our knowledge of the disease.

COVID-19 Biorepository

Covid-19

SARS-CoV 2

Coronavirus

COVID

While SARS-CoV-2 has some similarities to the SARS-CoV pathogen that led to an epidemic
in 2002 and 2003, there is much about the epidemiology, pathogenesis, clinical
presentation, diagnosis, and treatment of the novel virus that remains unknown.3
Additional research is needed to explore the nature of the virus, its spectrum of
disease, and potential therapies to combat its spread. The aim of this project will be to
establish a biorepository of blood samples from patients infected with SARS-CoV-2 that
can then be used by investigators to expand our understanding of COVID-19 and its
treatment and, in turn, improve patient outcomes.

The COVID-19 biorepository will accomplish the following specific aims:

  1. Establish a collection of biospecimens from patients with COVID-19.

  2. Establish a link between biospecimens and longitudinal individual patient data,
     which will be collected and stored in RedCap.

  3. Provide biospecimens and unique patient data to researchers investigating COVID-19.
     Separate IRB approval will be needed for these studies.

Establish a collection of biospecimens from patients with COVID-19.

Establish a link between biospecimens and longitudinal individual patient data

Provide biospecimens and unique patient data to researchers investigating COVID-19

COVID-19 Biorepository

About this trial

Study ID

Status

Type

Placebo

Accepting

Trial Timing

What is this trial about?

What are the participation requirements?

Locations

Location

Status